Proteomics International Signs Agreement with inVentiv Health Clinical
News Mar 07, 2014
Proteomics International has signed a collaborative agreement with inVentiv Health Clinical, a leading
provider of global clinical research and bioanalytical services.
Biosimilar and biologic development begins with extensive structural and functional characterization. Proteomics International provides structural characterization and QC testing of proposed and referenced products with an advanced suite of scientific instrumentation. These services complement inVentiv Health’s array of bioanalytical capabilities from clinical development through commercialization in support of biosimilar development.
The Proteomics International agreement with inVentiv Clinical offers developers the ability to seamlessly transition from characterization to clinical trials thereby streamlining the process and providing a competitive advantage in the race to market.
“We welcome the partnership with inVentiv as it represents a significant opportunity for us in furthering expansion into bio-generic markets,” said Dr. Richard Lipscombe, Managing Director of Proteomics International.
Dr. Lipscombe continued, “This collaboration will position both companies to better assist biosimilar and biologics developers in this emerging field and ever-changing regulatory environment.”
“The strengths of Proteomic International to demonstrate biosimilarity combined with inVentiv biologic clinical, commercial and consulting expertise is a winning solution for clients,” said Dr. George Scott, Vice President, Bioanalytical Services for inVentiv Clinical. “Together we offer the full breadth and scope of an integrated roadmap of biosimilar development services to help navigate the complex regulatory and development landscape from early strategic planning, clinical trial conduct, and registration to commercialization.”
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.